TELA Bio, Inc. (TELA) Dividend History

Company News

• TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

  TELA Bio, a medical technology company, announced the closing of its public offering of common stock and pre-funded warrants, raising $46 million. The company plans to use the proceeds for general corporate purposes.

  Benzinga
• TELA Bio Appoints Jeffrey Blizard to its Board of Directors

  MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024.

  GlobeNewswire Inc.
• TELA Bio Appoints Greg Firestone as Chief Commercial Officer

  MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company’s new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company’s commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company’s product lines.

  GlobeNewswire Inc.
• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

  GlobeNewswire Inc.
• Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates

  Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: VRTX